Quick Win By The Algorithm: Patent Title Granted

Quick Win By The Algorithm

On April 23, 2017, the I Know First algorithm issued a bullish forecast for Oramed Pharmaceuticals, Inc. (NASDAQ: ORMP). ORMP had a signal of 33.19 and a predictability of 0.05. Therefore, in accordance with the forecast, the company’s stock increased by 27.29% in just 3 days.

quick win

Oramed Pharmaceuticals Inc. (Oramed) is pharmaceutical company researching and developing drugs and vaccines.  Its most popular product is an orally indigestible insulin capsule in phase 2 clinical trial. The company is developing a method to treat diabetic patients with a capsule to be ingested orally, and not having the insulin injected.  The company was founded in 2006 and is headquartered in Jerusalem, Israel.

Top Stocks

 

Since April 19, 2017, ORMP has had a positive trend.  Recently, Beta Research has given ORMP an optimistic price target of $18.00.  That is more than double the stock’s current price in the $8 range.

On April 20, 2017, the company was granted by the European Patent Office a patent titled, “Methods and Compositions for Treating Diabetics: Capsules containing oil-based liquid compositions of combined therapeutic agents for treating diabetes.”  This important step is another factor to getting its flagship product to treat diabetes containing both insulin and GLP-1 analog into a capsule.  If the company can get the drug’s approval, this could serve as a more pain free treatment to treat diabetes.

This bullish forecast on ORMP was sent to the current I Know First subscribers on April 23, 2017.


Missed the latest trend? Looking for the next best market opportunity?
 Find out today’s stock forecast based on our advanced self-learning algorithm
Before making any trading decisions, consult the latest forecast as the algorithm constantly updates predictions daily. While the algorithm can be used for intra-day trading the predictability tends to become stronger with forecasts over longer time-horizons such as the 1-month, 3-month, and 1-year forecasts.